Biography：

Dr. Chuang earned his Sc.D. in Cancer Biology from Harvard University in 1997, with additional studies in Toxicology and Molecular Genetics. He continued his cancer research with a postdoctoral fellowship at Harvard. He later joined the National Cancer Institute (NCI) at the National Institute of Health (NIH) as a fellow, where he worked on radiation genomics. He has led the NCI’s Radiation Oncology Program in the Cancer Treatment and Diagnosis Department, overseeing a series of research grants at the NIH, including studies on radiation-induced signaling pathways, molecular mechanisms, normal tissue damage, and radiation-related gene research. In 2011, Dr. Chuang returned to National Taiwan University (NTU) and became the Director of the Graduate Institute of Biomedical Electronics and Bioinformatics at NTU. In his research career, Dr. Chuang has published 160 peer-reviewed articles and has notable experience as an editorial board member for scientific reports and as the editor-in-chief of Translational Cancer Research.

Biography：

Mien-Chie Hung, Ph.D. is the President of China Medical University in Taiwan. He was the vice president for basic research, the founding chair of the Department of Molecular and Cellular Oncology, and a Distinguished Endowed Chair at The University of Texas MD Anderson Cancer Center. He is a basic scientist with a translational vision and has significantly contributed to understanding the biology of receptor tyrosine kinases in cancer and developing combinational cancer therapies to overcome drug resistance. His lifetime h-index reaches 172 (Google). He served as a member of the Tang Prize Selection Committee. He was inducted as an Academician of the Academia Sinica in Taiwan in 2002, a Fellow of AAAS in 2010, and a TWAS member in 2023.

Biography：

Dr. Hui-Wen Lo is a seasoned basic and translational cancer biologist and a leader in the areas of primary and metastatic brain tumors, as well as, metastatic breast cancer. Her research program is robust and supported by multiple funding agencies, including NCI, DoD, and other agencies. She has published more than 110 peer-reviewed publications. Dr. Lo is a dedicated educator and mentor who has trained many trainees in her previous institutions Duke University School of Medicine and Wake Forest School of Medicine, and currently trains multiple trainees. In addition to her scholarly activities, Dr. Lo has been serving in many leadership roles. Previously at Wake Forest School of Medicine, she served as the Associate Director for Shared Resources Management and Associate Director for Basic Sciences for the NCI-designated Wake Forest Baptist Comprehensive Cancer Center. In that role, she led three research programs, coordinated interprogrammatic collaborations, and contributed to the successful renewal of the NCI Cancer Center Support Grant in 2022. At her current Institution of McGovern Medical School, the University of Texas Health Science Center at Houston, she continues to play multiple leadership roles as the Director of the Metastatic Brain Tumor Program and the Vice Chair of Research in the Department of Neurosurgery, the home of 18 PhD faculty and 12 physician-scientists. Dr. Lo has brought in multiple grants with >5 million dollars to her current institution since September 2022. Her laboratory continues to focus on the biology and treatments of hard-to-treat human cancers.

Dr. James Cai is a Professor of Computational Systems Biology with a joint appointment in the Veterinary Integrative Biosciences and Electrical & Computer Engineering departments at Texas A&M University. His research integrates genomics, computational statistics, and data science, employing machine learning, graph theory, and quantum computation to understand cellular behaviors. Dr. Cai has made significant contributions to the field of single-cell computational biology, including developing the easy-to-use desktop application for single-cell gene expression analysis without programming, and advanced machine learning methods such as scTenifoldXct for predicting cell-cell interactions, scTenifoldKnk for performing virtual gene knockouts, and scTenifoldNet for constructing and comparing single-cell gene regulatory networks. He also introduced QuantumGRN, a quantum circuit model for inferring gene regulatory networks. With expertise in data science, machine learning, and quantum computing, Dr. Cai's interdisciplinary research contributes to our understanding of cellular behavior and genetic disease mechanisms, shaping future diagnostic and therapeutic strategies. 

Dr. Danny Chou is an Associate Professor of Pediatrics (Endocrinology and Diabetes) and by courtesy, of Chemical & Systems Biology at Stanford University. He received his PhD from Harvard University in 2011. He then moved to MIT, where he was a JDRF Postdoctoral Fellow in the Department of Chemical Engineering. Danny started his independent career at the University of Utah in 2014. At Utah, Danny's research focused on protein and peptide therapeutics for the treatment of Type 1 Diabetes and other human diseases. In 2020, Danny moved his research lab to Stanford University to continue their efforts in developing novel insulin therapeutics. Danny has received recognitions including an American Peptide Society Early Career Lectureship, Boulder Peptide Society Young Investigator Award, JDRF Career Development Award, Vertex Scholar, JDRF Postdoctoral Fellowship, ADA Junior Faculty Award, and an NIDDK Catalyst Award.

Biography：

Dr. Hsiao-Ling Hung is currently an independent consultant providing regulatory strategy services to over 20 biopharmaceutical companies, and President of Taiwanese American Association of Biotechnology. 

Her past professional experience includes Senior VP, RA/QA at Ambrx, a public clinical-stage biotech company that focuses on developing Engineered Precision Biologics, Sr Director in Global Regulatory Sciences at BMS, leading regulatory strategy and managing regulatory staff for the Opdivo portfolio, Director of US and International Regulatory Affairs at Johnson & Johnson in Oncology and Immunology.

Prior to a career in regulatory affairs, Hsiao-Ling was a preclinical scientist for over 20 years, leading the discovery and preclinical research programs of compounds across multiple therapeutic areas.

Hsiao-Ling received a B.S. in Medical Technology from the National Taiwan University and a Ph.D. in Pathology and Molecular Biology from the University of Pennsylvania.

Dr. Yi-Hsiang Hsu is a Vice Presdient at Profound Therapeutic and also an Associate Professor of Medicine at Harvad Medical School. His research interests include 1) genetic contribution of common aging relevant disorders using population-based next generation whole genome sequencing, exome-sequencing and GWAS approaches; 2) statistical method development on multiple-phenotype association analyses; and 3) identifying biomarkers of osteoporosis using metabolomics. He received his BS from Taipei Medical School, Taiwan. He then pursued his MS in Epidemiology at National Taiwan University and received ScD from Harvard School of Public Health. Before he became the VP at Profound Therapeutic, he served as a Scientific Director at Amgen.

Dr. Pan leads the Rapid Testing Team, supporting the entire Biologics Development Organization for drug substance and drug product development testing activities at Gilead Sciences. Being passionate about innovation, she delivered the cell line technology development for the Gilead-format bispecific modality, designed tool cell lines for CAR T-

cell therapy analytical testing, and expanded biologics development testing capability and capacity via establishing next-generation cell line and process analytics. She also collaborates with the Data Sciences Team to increase cross-functional workflows’ operational efficiency. Dr. Pan obtained her Ph.D. degree in Biochemistry at UC-Irvine, 

followed by a post-doctoral fellowship at the Scripps Research Institute.

Dr. Shu-Hong Lin is a versatile computational scientist with a passion for leveraging cutting-edge technologies to drive innovation in biotechnology. Based in Cambridge, MA, Dr. Lin holds a Ph.D. in Cancer Biology with a focus on Biostatistics, Bioinformatics, and Systems Biology from the University of Texas MD Anderson Cancer Center. With a proven track record in academia, government, and industry, Dr. Lin has honed his expertise in bioinformatics, epidemiological methods, and machine learning. His career highlights include roles such as Senior Scientist in Computational Biology at BioNTech US, where he spearheaded the integration of diverse datasets to drive early discovery of targets for TCR T cell therapy. He also played a crucial role in the development of RNA translatability predictors using pre-trained neural network models. Previously, as a Postdoctoral Fellow at the National Cancer Institute, Dr. Lin contributed to research on the safety of nucleoside reverse transcriptase inhibitors (NRTI) and explored the link between somatic mosaicism and infectious disease risk. His work has resulted in numerous publications in prestigious journals, showcasing his commitment to advancing scientific knowledge.

Biography：

Sabrina Hsueh, PhD, FAMIA, is a trailblazing Ethical AI and External Innovation Lead at Pfizer, renowned for driving health AI innovations and responsible AI practices in healthcare and life sciences. She fosters the integration of AI and medicine across the end-to-end pipeline of AI innovation and adoption with a focus on humanity and equity. As a thought leader, Dr. Hsueh actively contributes to private-public partnerships, such as the NIST AI Safety Consortium, and leads community efforts to shape AI standards, including the IEEE P7008 Standards on AI Nudging and Real-World Data and Model Labels for AI.

An influential community leader, Dr. Hsueh serves on the Practitioner Board of the Association of Computing Machinery (ACM) and chairs the AI Evaluation Showcase at the American Medical Informatics Association (AMIA). She co-chairs the Trustworthy AI/Real-World Data for AI Work Group with Harvard Medical School DCI-Network, where stakeholders collaboratively develop guidelines for the responsible use of AI and understanding the pathways to AI governance. Previously at IBM Research, Dr. Hsueh led the Health Informatics Community, was elected into the IBM Academy of Technology, and actively contributed to scientific committees and workgroups in health informatics and data science.

A prolific author, Dr. Hsueh has published over 80 technical papers and patents, including the textbook “Personal Health Informatics: Patient Participation in Precision Health.”; She is deeply committed to mentoring the next generation of multi-disciplinary AI innovators, leading the Women in AMIA Steering Committee, co-hosting the ACM/AMIA podcast series, and co-founding a special interest group with IMIA/WHO to advance global health equity.

Dr. Yu-Chiao (Chris) Chiu is an Assistant Professor of Medicine in the Division of Oncology and the UPMC Hillman Cancer Center at the University of Pittsburgh. His research interests include bioinformatics, machine learning, cancer genomics, and pharmacogenomics. The goal of his laboratory is to systematically model genomics and pharmacogenomics to gain a better understanding of cancer biology and improve cancer therapy. Dr. Chiu has been honored with the prestigious NIH/NCI K99/R00 Pathway to Independence Award for his work in developing deep-learning methods to predict the responses of cancer cells to treatments. Since joining the University of Pittsburgh in 2022, he has received five research awards from the NIH Office of the Director, the Pittsburgh Liver Research Center, the UPMC Hillman Cancer Center, and the Leukemia Research Foundation. Furthermore, he was named a Hillman Early Career Fellow for Innovative Cancer Research. To date, Dr. Chiu has published more than 50 journal articles and 70 conference articles/abstracts. He is an active member of the bioinformatics community and has chaired sessions at the IEEE BIBM and ICIBM conferences. He serves as an Organizing Committee member for the IEEE-EMBS International Conference on Biomedical and Health Informatics (BHI) in 2023 and 2024.

Born and raised in Taiwan, Kuan-lin “Kuan” Huang is an Assistant Professor of Genetics and Genomic Sciences & Artificial Intelligence. He leads the Precision Omics Lab at the Icahn School of Medicine at Mount Sinai. After being the only graduate to earn two Honors (Molecular Biology & Studio Art) at Wesleyan University, he completed his Ph.D. in Statistical Genomics and Postdoc in Multi-omic Software Development at Washington University in St. Louis. He has authored over 70 peer-reviewed publications including lead authorship in the top scientific journals, and is the author of the best-seller “Solve It Yourself.” Kuan was a co-founder/CEO of the startup DeepGene in grad school and currently serves as the Co-Founder and Chief Unboxer of OpenBoxScience.Org. A good day of his life typically involves great people, hikes, books, dark chocolate, bubble tea, surfing, tennis; and a 20-minute nap.

Dr. Pei-Hua (Candice) Chu is a board-certified veterinary clinical pathologist and an assistant professor at Texas A&M University. She earned her DVM degree from National Taiwan University and completed her PhD in veterinary pathology and residency training at Texas A&M University. Before her current role, she was an assistant professor of clinical pathology at the University of Pennsylvania. Dr. Chu’s research focuses on gene and microRNA expression related to chronic kidney disease, particularly the potential of urinary microRNAs as early biomarkers for dogs and cats. Her research integrates bioinformatics, digital cytology, and artificial intelligence in veterinary medicine. She recently published a review paper titled “ChatGPT in veterinary medicine: a practical guidance of generative artificial intelligence in clinics, education, and research” and was invited to speak at the American Veterinary Internal Medicine Forum and the Veterinary Information Network (VIN), the largest veterinary online community. n addition to her research, she teaches veterinary clinical pathology using innovative methods, including her popular Instagram page @Vet.Clin.Path.Professor.